Dan Ollendorf
@dano-hta.bsky.social
370 followers 94 following 38 posts
Clin epi / health economics, focus on the evidence and science, fan of sanity
Posts Media Videos Starter Packs
Reposted by Dan Ollendorf
dano-hta.bsky.social
Was great fun to write this with Sarah Emond! A value-based approach could be used to reduce traditional access barriers and possibly mitigate back-end legislative remedies...
Reposted by Dan Ollendorf
evanurquhart.bsky.social
Val and I checked repeatedly because we simply couldn't believe no national or local news organizations covered this letter from 18 AGs in support of trans youth care and against FTC overreach.

If you find any stories, let us know, but it seems to be our exclusive.
assignedmedia.org
On Friday 18 blue state attorneys general BLASTED the Federal Trade Commission, telling it to back off trans youth healthcare and warning of an insidious attempt to reshape the regulation of medicine in the US.

And nobody covered it.

www.assignedmedia.org/breaking-new...
State AGs Defend Trans Americans in Stunning Rebuke to Trump’s FTC — Assigned
Eighteen state Attorneys General unite to stand up in defense of trans Americans, in opposition to a Federal Trade Commission investigation into trans healthcare.
www.assignedmedia.org
Reposted by Dan Ollendorf
bradlander.bsky.social
I was back at 26 Federal Plaza today, where an ICE agent violently threw this bereft woman to the ground in front of her kids. She had not touched him. She did not pose any threat. She had to be taken to the hospital. (🎥: Elias Eliahu)
dano-hta.bsky.social
There's one typo, referring to the combo vaccine as "MMRW"...
Reposted by Dan Ollendorf
adrianna.bsky.social
A new paper led by Harvard Health Policy PhD student Ye Shen finds that, in the current policy environment, more than six in ten kids will have been enrolled in Medicaid for some period of time by their 18th birthday; the program is absolutley critical for children.

jamanetwork.com/journals/jam...
Reposted by Dan Ollendorf
phillewis.bsky.social
Here’s what a Ball State University employee said that led to their termination:

Suzanne Swierc

Let me be clear: if you think Charlie Kirk was a wonderful person, we can't be friends.
His death is a tragedy, and I can and do feel for his wife and children.
I believe in the Resurrection, and while it's difficult, I can and do pray for his soul.
Charlie Kirk's death is a reflection of the violence, fear, and hatred he sowed. It does not excuse his death, AND it's a sad truth.
The shooting is a tragedy, and I can and do feel for a college campus experiencing an active shooter situation.
The deaths of Melissa and Mark Hortman, the children shot and killed in Minneapolis last month, and the children shot in Colorado today are all tragedies that also deserve your attention.
Charlie Kirk excused the deaths of children in the name of the second amendment.
dano-hta.bsky.social
Make your voice heard -- your opportunity to comment coming up! @htaiorg.bsky.social @cda-amc.bsky.social @nicecomms.bsky.social
icer-review.bsky.social
The first HEMA Draft Report will be published on September 24th, which will be open to public comment until October 15th.

Mark your calendars and submit your public comments via [email protected]!

Learn more: hemamethods.org
Health Economics Methods Advisory
hemamethods.org
Reposted by Dan Ollendorf
icer-review.bsky.social
The Health Economics Methods Advisory (HEMA) has a new website! hemamethods.org

HEMA was convened by leaders at 3 global HTA organizations: ICER, @nicecomms.bsky.social, and @cda-amc.bsky.social
to critically and independently examine and assess new methods and processes.
Health Economics Methods Advisory
hemamethods.org
Reposted by Dan Ollendorf
icer-review.bsky.social
The first HEMA Draft Report will be published on September 24th, which will be open to public comment until October 15th.

Mark your calendars and submit your public comments via [email protected]!

Learn more: hemamethods.org
Health Economics Methods Advisory
hemamethods.org
dano-hta.bsky.social
#RIP to a kind, intelligent, and thoughtful researcher and evidence advocate. But as you can see from this @nytimes.com piece, also a true leader to the end:

www.nytimes.com/2025/08/03/h...
A Cancer Patient Chose Assisted Death. That Wasn’t the Last Hard Choice.
www.nytimes.com
Reposted by Dan Ollendorf
tuftscevr.bsky.social
Great application of our CEA Registry at the #Vanderbilt Center for Health Economic Modeling: 11 international fellows from #LMICs used the Registry to conduct CEAs of public health interventions.

Read more at: tinyurl.com/88varaue

@peterneumann11.bsky.social #ISPOR
VUMC researchers host international fellows for economic evaluation, decision science training
Vanderbilt recently hosted 11 international fellows to provide training to help them address public health issues in their home countries.
tinyurl.com
Reposted by Dan Ollendorf
richferro.com
The Medsky feed is close to 200 likes, so if you can please support by liking, sharing, and pinning it!

I know this sounds silly but the more engagement the feed receives the more likely it is that people will see there’s a dedicated space on Bluesky to discuss and share healthcare information.
dano-hta.bsky.social
Importantly, much work still to be done to explore the applicability of available frameworks and integration into #HTA processes. I look forward to the work ahead.
tuftscevr.bsky.social
Traditional #valueassessment lacks methods to evaluate #oncology combination txs, posing challenges for drugmakers, HTA bodies, and payers.

In a new commentary in Frontiers in Pharmacology, CEVR’s Dan Ollendorf et al explore available frameworks and chart a path forward: tinyurl.com/kh84ueb4
Frontiers | Value attribution for oncology combination regimens: going beyond frameworks to balance innovation, access, and affordability
Combination therapies are a mainstay in cancer treatment, but reimbursement access can be limited, owing to complexities around value assessment and pricing,...
tinyurl.com
Reposted by Dan Ollendorf
tuftscevr.bsky.social
Traditional #valueassessment lacks methods to evaluate #oncology combination txs, posing challenges for drugmakers, HTA bodies, and payers.

In a new commentary in Frontiers in Pharmacology, CEVR’s Dan Ollendorf et al explore available frameworks and chart a path forward: tinyurl.com/kh84ueb4
Frontiers | Value attribution for oncology combination regimens: going beyond frameworks to balance innovation, access, and affordability
Combination therapies are a mainstay in cancer treatment, but reimbursement access can be limited, owing to complexities around value assessment and pricing,...
tinyurl.com
Reposted by Dan Ollendorf
dano-hta.bsky.social
Excited to contribute to a special issue of @BMJ_EBM, offering timely analysis on India’s experience of institutionalizing health technology assessment, with lessons for other LMICs.
Read on to see an adaptation of a @icer-review.bsky.social HTA report for the Indian context! ⬇
bit.ly/4h2UGGC
Celebrating Ten Years of the international Decision Support Initiative
Over the last decade, iDSI has partnered with countries to develop evidence-informed priority-setting institutions and processes. Read our blog for a summary of key successes, challenges, and lessons ...
bit.ly
Reposted by Dan Ollendorf
icer-review.bsky.social
This Friday -- at 12 PM ET join us for the virtual public meeting on the comparative clinical effectiveness and value of tolebrutinib (made by Sanofi) for the treatment of secondary progressive multiple sclerosis.

Register here: shorturl.at/razPI #heor #hta
CTAF June 2025 Public Meeting on Secondary Progressive Multiple Sclerosis
events.zoom.us
Reposted by Dan Ollendorf
brittanytrang.com
The FDA's AI, Elsa, can't even tell you who the FDA leadership is.

Despite being updated thru April 2024, Elsa exclusively listed leaders who have left the FDA, including 3 that retired in 2022-23 and one that left in '21.

More on Elsa (& which version of Claude it uses), only at AI Prognosis: 🖥️🩺
FDA's AI tool, Elsa, is here. 'The stupidest big fuss they ever made'
This is the web edition of STAT's AI Prognosis, our subscriber-exclusive newsletter.
www.statnews.com
Reposted by Dan Ollendorf